Teva Pharmaceutical Industries has launched Olanzapine and Fluoxetine Capsules USP 6mg/25mg, 12mg/25mg, 6mg/50mg, and 12mg/50mg.
The Olanzapine and Fluoxetine Capsules are the company's generic equivalent to Symbyax.
Lilly USA commercializes Symbyax, which is approved for the acute treatment of treatment-resistant depression and bipolar I depression in adults.
According to IMS sales data, Symbyax had annual sales of approximately $82m in the US.
Teva is a global pharmaceutical company with a focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/teva-introduces-generic-equivalent-to-symbyax-in-us-220612
